AbbVie received FDA approval for a first in class, all oral, fixed duration regimen combining VENCLEXTA and acalabrutinib for previously untreated chronic lymphocytic leukemia. The company announced a ...

The approval was based on the AMPLIFY trial, which evaluated acalabrutinib alongside venetoclax in adults with previously untreated CLL without del(17p) or TP53 mutation.

Mitochondrial DNA heteroplasmy is independently associated with an increased risk of CLL, suggesting potential as a novel biomarker for early risk identification.

A newly approved combination of acalabrutinib plus venetoclax gives with newly diagnosed chronic lymphocytic leukemia (CLL) another chemotherapy-free option that is taken for a fixed period of time ...

The FDA has approved the first all-oral, fixed-duration first-line regimen for treatment of chronic lymphocytic leukemia and ...

AstraZeneca (LSE:AZN) received US FDA approval for CALQUENCE as an all oral, fixed duration therapy for chronic lymphocytic leukemia and small lymphocytic lymphoma. The European Medicines Agency ...

FDA cleared acalabrutinib plus venetoclax as the only all-oral, fixed-dose combination option for first-line, treatment-naïve CLL/SLL. Phase 3 AMPLIFY showed superior PFS versus chemoimmunotherapy, ...

AbbVie (ABBV) said Friday that the U.S. FDA has approved a supplemental new drug application for its combination regimen of Venclexta (venetoclax) and acalabrutinib to treat previously untreated ...

Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...

Chronic lymphocytic leukemia (CLL) is a type of blood cancer that affects white blood cells called lymphocytes. There are many types of leukemia, and CLL is a common type in adults. This type of ...